Functional Screening Identifies Human miRNAs that Modulate Adenovirus Propagation in Prostate Cancer Cells

Jasmina Hodzic1, Daoud Sie2, Annaleen Vermeulen3

  • 11 Department of Medical Oncology, VU University Medical Center , Amsterdam, Netherlands .

Human Gene Therapy
|January 25, 2017
PubMed

Insights

Oncolytic adenoviruses show promise for cancer treatment, but efficacy varies. This study found that miR-26b can enhance adenovirus efficacy in prostate cancer cells by boosting cell death and viral spread.

Area of Science:

  • Oncolytic virotherapy
  • Molecular oncology
  • MicroRNA biology

Background:

  • Oncolytic adenoviruses are a novel class of anticancer agents with variable efficacy.
  • Host cell microRNAs (miRNAs) play critical roles in viral replication and host-pathogen interactions.
  • Understanding miRNA influence on adenovirus replication in cancer is key to improving oncolytic virotherapy.

Purpose of the Study:

  • To investigate the impact of host cell miRNA expression on adenovirus replication in human prostate cancer cells.
  • To identify specific miRNAs that modulate adenovirus-induced cell death and viral propagation.
  • To explore the potential of targeting miRNAs for enhanced oncolytic adenovirus therapy.

Main Methods:

  • Analysis of human miRNA expression profiles in prostate cancer cells following adenovirus infection.
  • Functional screening using synthetic miRNA mimics and inhibitors to assess effects on adenovirus replication and cell death.
  • Evaluation of miRNA effects on adenovirus-mediated NF-κB activation and viral progeny release.

Main Results:

  • Adenovirus infection broadly affected miRNA expression, with specific downregulation of miR-222.
  • A subset of miRNAs promoted adenovirus-induced prostate cancer cell death, but typically not viral propagation.
  • Overexpression of miR-26b specifically enhanced adenovirus-mediated cell death, inhibited NF-κB activation, and promoted viral replication and spread.

Conclusions:

  • miR-26b acts as a positive regulator of oncolytic adenovirus efficacy in prostate cancer.
  • Targeting miR-26b could be a viable strategy to improve oncolytic adenovirus therapy for prostate cancer.
  • Combined therapy with oncolytic adenoviruses and miR-26b modulation holds promise for more effective prostate cancer treatment.